These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 21329553)

  • 1. The evidence-based pharmacological treatment of paediatric ADHD.
    Vaughan BS; March JS; Kratochvil CJ
    Int J Neuropsychopharmacol; 2012 Feb; 15(1):27-39. PubMed ID: 21329553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medication options when treating children and adolescents with ADHD: interpreting the NICE guidance 2006.
    Harpin VA
    Arch Dis Child Educ Pract Ed; 2008 Apr; 93(2):58-65. PubMed ID: 18356307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder.
    Gibson AP; Bettinger TL; Patel NC; Crismon ML
    Ann Pharmacother; 2006 Jun; 40(6):1134-42. PubMed ID: 16735655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) and comorbid disorders].
    Wiesegger G; Kienbacher C; Pellegrini E; Scheidinger H; Vesely C; Bangerl W; Friedrich M
    Neuropsychiatr; 2007; 21(3):187-206. PubMed ID: 17915180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
    Biederman J; Spencer T; Wilens T
    Int J Neuropsychopharmacol; 2004 Mar; 7(1):77-97. PubMed ID: 14733627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychopharmacological treatment of ADHD symptoms in children with autism spectrum disorder.
    Handen BL; Taylor J; Tumuluru R
    Int J Adolesc Med Health; 2011; 23(3):167-73. PubMed ID: 22191179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults.
    Santosh PJ; Sattar S; Canagaratnam M
    CNS Drugs; 2011 Sep; 25(9):737-63. PubMed ID: 21870887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of one-year pharmacological treatment of adult attention-deficit/hyperactivity disorder (ADHD): an open-label prospective study of time in treatment, dose, side-effects and comorbidity.
    Fredriksen M; Dahl AA; Martinsen EW; Klungsøyr O; Haavik J; Peleikis DE
    Eur Neuropsychopharmacol; 2014 Dec; 24(12):1873-84. PubMed ID: 25453480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine as an adjunct therapy in the treatment of co-morbid attention-deficit/hyperactivity disorder in children and adolescents with bipolar I or II disorder.
    Chang K; Nayar D; Howe M; Rana M
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):547-51. PubMed ID: 19877979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attention-deficit-hyperactivity disorder: an update.
    Dopheide JA; Pliszka SR
    Pharmacotherapy; 2009 Jun; 29(6):656-79. PubMed ID: 19476419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atomoxetine may improve methylphenidates' efficacy in treatment of ADHD?
    Niederhofer H
    Psychiatr Danub; 2009 Sep; 21(3):330. PubMed ID: 19794351
    [No Abstract]   [Full Text] [Related]  

  • 16. Drugs for treatment of ADHD.
    Treat Guidel Med Lett; 2011 May; 9(105):23-8; quiz 2 p following 28. PubMed ID: 21519317
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
    Kaplan G; Newcorn JH
    Pediatr Clin North Am; 2011 Feb; 58(1):99-120, xi. PubMed ID: 21281851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving decision making in the treatment of ADHD.
    Vitiello B
    Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
    [No Abstract]   [Full Text] [Related]  

  • 19. Factors associated with atomoxetine efficacy for treatment of attention-deficit/hyperactivity disorder in children and adolescents.
    Scott NG; Ripperger-Suhler J; Rajab MH; Kjar D
    J Child Adolesc Psychopharmacol; 2010 Jun; 20(3):197-203. PubMed ID: 20578932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Close up on atomoxetine: a nonstimulant choice for treating ADHD.
    Allen C; Pitcock J
    Adv Nurse Pract; 2006 Mar; 14(3):39-40, 42-3, 78. PubMed ID: 16548127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.